Adenovirus, Adeno-Associated Virus and Measles virus are attractive candidates to create viral vectors for gene therapy and vector vaccines. With Batavia Biosciences’ extensive expertise, we make a suitable vector, starting from the DNA sequence, the selected vaccine antigen(s) or gene therapy target.
Stable virus clones can then be selected and produced either as a research batch for POC studies or as a pre-Master Virus Seed Stock that can then be transferred to a GMP facility for production of a Master Virus Seed. By in-house screening these seed stocks can be fully characterized for stability, potency, purity, gene or antigen expression etc to ensure the correct candidate is selected.
Reference projects include; Hemorrhagic fevers, Malaria, TB, HIV, HPV, HCV, Dengue and Chikungunya.